$AXSM
Axsome Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024124758 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $104.8M
YoY Change 81.27%
Cost Of Revenue $8.437M
YoY Change 29.2%
Gross Profit $96.33M
YoY Change 87.91%
Gross Profit Margin 91.95%
Selling, General & Admin $95.56M
YoY Change 14.88%
% of Gross Profit 99.21%
Research & Development $45.39M
YoY Change 57.78%
% of Gross Profit 47.12%
Depreciation & Amortization $2.061M
YoY Change 17.77%
% of Gross Profit 2.14%
Operating Expenses $141.0M
YoY Change 25.9%
Operating Profit -$62.62M
YoY Change 0.81%
Interest Expense -$1.978M
YoY Change 160.26%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$64.60M
YoY Change 2.74%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$64.60M
YoY Change 3.86%
Net Earnings / Revenue -61.67%
Basic Earnings Per Share -$1.34
Diluted Earnings Per Share -$1.34
COMMON SHARES
Basic Shares Outstanding 48.46M 48.00M
Diluted Shares Outstanding 48.14M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $327.3M
YoY Change -21.43%
Cash & Equivalents $327.3M
Short-Term Investments
Other Short-Term Assets $13.41M
YoY Change 97.22%
Inventory $14.27M
Prepaid Expenses
Receivables $124.1M
Other Receivables $0.00
Total Short-Term Assets $479.1M
YoY Change -6.38%
LONG-TERM ASSETS
Property, Plant & Equipment $683.0K
YoY Change -29.66%
Goodwill $12.00M
YoY Change -0.35%
Intangibles $48.50M
YoY Change -11.64%
Long-Term Investments
YoY Change
Other Assets $15.39M
YoY Change 9.14%
Total Long-Term Assets $82.35M
YoY Change -7.58%
TOTAL ASSETS
Total Short-Term Assets $479.1M
Total Long-Term Assets $82.35M
Total Assets $561.5M
YoY Change -6.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $64.25M
YoY Change 120.82%
Accrued Expenses $122.0M
YoY Change 54.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.280M
YoY Change
Total Short-Term Liabilities $196.2M
YoY Change 71.1%
LONG-TERM LIABILITIES
Long-Term Debt $180.0M
YoY Change 1.44%
Other Long-Term Liabilities $89.42M
YoY Change 128.11%
Total Long-Term Liabilities $180.0M
YoY Change 1.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $196.2M
Total Long-Term Liabilities $180.0M
Total Liabilities $468.6M
YoY Change 41.41%
SHAREHOLDERS EQUITY
Retained Earnings -$1.048B
YoY Change 42.2%
Common Stock $1.141B
YoY Change 13.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $92.90M
YoY Change
Total Liabilities & Shareholders Equity $561.5M
YoY Change -6.56%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$64.60M
YoY Change 3.86%
Depreciation, Depletion And Amortization $2.061M
YoY Change 17.77%
Cash From Operating Activities -$18.63M
YoY Change -65.21%
INVESTING ACTIVITIES
Capital Expenditures $90.00K
YoY Change -76.32%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K
YoY Change -76.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.40M
YoY Change -8.89%
NET CHANGE
Cash From Operating Activities -18.63M
Cash From Investing Activities -90.00K
Cash From Financing Activities 30.40M
Net Change In Cash 11.68M
YoY Change -156.83%
FREE CASH FLOW
Cash From Operating Activities -$18.63M
Capital Expenditures $90.00K
Free Cash Flow -$18.72M
YoY Change -65.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001579428
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37635
dei Entity Registrant Name
EntityRegistrantName
AXSOME THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4241907
dei Entity Address Address Line1
EntityAddressAddressLine1
One World Trade Center
dei Entity Address Address Line2
EntityAddressAddressLine2
22nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
332-3241
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
dei Trading Symbol
TradingSymbol
AXSM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48462376
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
327341000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
386193000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
124096000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
94820000
CY2024Q3 us-gaap Inventory Net
InventoryNet
14265000
CY2023Q4 us-gaap Inventory Net
InventoryNet
15135000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13411000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8115000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
479113000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
504263000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
683000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
846000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5730000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6772000
CY2024Q3 us-gaap Goodwill
Goodwill
12042000
CY2023Q4 us-gaap Goodwill
Goodwill
12042000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
48501000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53286000
CY2024Q3 us-gaap Other Inventory Noncurrent
OtherInventoryNoncurrent
15389000
CY2023Q4 us-gaap Other Inventory Noncurrent
OtherInventoryNoncurrent
11027000
CY2024Q3 us-gaap Assets
Assets
561458000
CY2023Q4 us-gaap Assets
Assets
588236000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
64253000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
40679000
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
122176000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
90501000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1627000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1267000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8131000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
6407000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
196187000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
138854000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
82980000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
73300000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
180002000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
178070000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6440000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7035000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2951000
CY2024Q3 us-gaap Liabilities
Liabilities
468560000
CY2023Q4 us-gaap Liabilities
Liabilities
397259000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48436108
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48436108
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47351363
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47351363
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1140768000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1026543000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1047875000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-835571000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
92898000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
190977000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
561458000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
588236000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104762000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57794000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
266927000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
199070000
CY2024Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
8437000
CY2023Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6532000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
22789000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
18687000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45388000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28767000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
132071000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67141000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
95564000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
83188000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
298088000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
236314000
CY2024Q3 axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
16391000
CY2023Q3 axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
-180000
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
17139000
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
5711000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1606000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1607000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4785000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4768000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
167386000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
119914000
us-gaap Costs And Expenses
CostsAndExpenses
474872000
us-gaap Costs And Expenses
CostsAndExpenses
332621000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-62624000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-62120000
us-gaap Operating Income Loss
OperatingIncomeLoss
-207945000
us-gaap Operating Income Loss
OperatingIncomeLoss
-133551000
CY2024Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-1978000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-757000
us-gaap Investment Income Net
InvestmentIncomeNet
-4359000
us-gaap Investment Income Net
InvestmentIncomeNet
-5751000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64602000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62877000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-212304000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-139302000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-678000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1285000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-64602000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-62199000
us-gaap Net Income Loss
NetIncomeLoss
-212304000
us-gaap Net Income Loss
NetIncomeLoss
-140587000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.14
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48140519
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48140519
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47117196
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47117196
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47703508
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47703508
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44783380
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44783380
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
109556000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12943000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
387000
CY2023Q1 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
1011000
CY2023Q1 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
867000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11218000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
111812000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15922000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6570000
CY2023Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
211378000
CY2023Q2 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
624000
CY2023Q2 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
333000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-67170000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
278804000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17237000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4317000
CY2023Q3 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
31704000
CY2023Q3 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
355000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-62199000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
269508000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
190977000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20533000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2501000
CY2024Q1 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
1618000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-68357000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
144036000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21709000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6741000
CY2024Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
11039000
CY2024Q2 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
1328000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-79345000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
102852000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21992000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20290000
CY2024Q3 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
12839000
CY2024Q3 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
473000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-64602000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
92898000
us-gaap Profit Loss
ProfitLoss
-212304000
us-gaap Profit Loss
ProfitLoss
-140587000
us-gaap Share Based Compensation
ShareBasedCompensation
63232000
us-gaap Share Based Compensation
ShareBasedCompensation
43705000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4785000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4768000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1932000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2120000
us-gaap Depreciation
Depreciation
403000
us-gaap Depreciation
Depreciation
326000
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
17139000
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
5711000
axsm Non Cash Lease Expense
NonCashLeaseExpense
1042000
axsm Non Cash Lease Expense
NonCashLeaseExpense
1115000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
697000
axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-235000
axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-59000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
29276000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
40716000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1873000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3268000
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
5296000
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
4018000
axsm Non Current Inventory And Other Assets
NonCurrentInventoryAndOtherAssets
169000
axsm Non Current Inventory And Other Assets
NonCurrentInventoryAndOtherAssets
-601000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23574000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9507000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
30395000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
25091000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102208000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-114718000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
240000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
575000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-240000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-575000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
85000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2297000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
660000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24365000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
258750000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
487000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
15668000
axsm Proceeds From Issuance Of Common Stock Upon Exercise Of Options And Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUponExerciseOfOptionsAndUnderEmployeeStockPurchasePlan
29532000
axsm Proceeds From Issuance Of Common Stock Upon Exercise Of Options And Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUponExerciseOfOptionsAndUnderEmployeeStockPurchasePlan
11274000
axsm Payment Of Contingent Consideration
PaymentOfContingentConsideration
-5735000
axsm Payment Of Contingent Consideration
PaymentOfContingentConsideration
-4489000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3419000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1555000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43596000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
331015000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58852000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
215722000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
386193000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200842000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
327341000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
416564000
us-gaap Interest Paid Net
InterestPaidNet
14935000
us-gaap Interest Paid Net
InterestPaidNet
11862000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7764000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
4890000
CY2024Q3 axsm Number Of Approved Products
NumberOfApprovedProducts
2
CY2024Q3 axsm Number Of Not Yet Approved Product Candidates
NumberOfNotYetApprovedProductCandidates
3
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1047900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock-based compensation expense; determination of fair value of warrants; accounting for research and development costs; accounting for acquisitions; impairments of goodwill and the intangible asset; determination of fair value of contingent consideration; chargebacks, cash discounts, sales rebates, returns and other adjustments; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
327300000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash deposits at financial institutions, which cash deposits exceed insured limits. At September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the majority of the Company’s cash was held by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> financial institutions and amounts on deposit were in excess of government-provided insurance limits. The Company </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">places its cash and cash equivalents in what it believes to be high credit quality banks and money market funds and has not recognized any losses from credit risks on such accounts since inception. See Accounts Receivables, net below for further information.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Risk, Other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">- </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has a limited number of contract manufacturers for its products. At times, the Company may have only one manufacturer or supplier for its products.</span></p>
CY2024Q3 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
2
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2024Q3 us-gaap Goodwill
Goodwill
12000000
CY2023Q4 us-gaap Goodwill
Goodwill
12000000
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
60 days or less
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2024Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2024Q3 us-gaap Advertising Expense
AdvertisingExpense
20700000
us-gaap Advertising Expense
AdvertisingExpense
75000000
CY2023Q3 us-gaap Advertising Expense
AdvertisingExpense
28100000
us-gaap Advertising Expense
AdvertisingExpense
76200000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 axsm Trade Receivables
TradeReceivables
138395000
CY2023Q4 axsm Trade Receivables
TradeReceivables
107320000
CY2024Q3 axsm Reserves For Variable Consideration
ReservesForVariableConsideration
14299000
CY2023Q4 axsm Reserves For Variable Consideration
ReservesForVariableConsideration
12500000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
124096000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
94820000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
7749000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5534000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
8192000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
10287000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8824000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9643000
CY2024Q3 axsm Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
24765000
CY2023Q4 axsm Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
25464000
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2024Q3 us-gaap Inventory Net
InventoryNet
14265000
CY2023Q4 us-gaap Inventory Net
InventoryNet
15135000
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
10500000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
10329000
CY2024Q3 axsm Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
24765000
CY2023Q4 axsm Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
25464000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
63800000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10514000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53286000
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
63800000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15299000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
48501000
CY2024Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P8Y
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1607000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6375000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6375000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
6375000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
6392000
CY2024Q3 axsm Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
21377000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
48501000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
79707000
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
17139000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-5735000
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
91111000
CY2024Q3 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
15328000
CY2023Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6503000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19367000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
20457000
CY2024Q3 axsm Accrued Selling General And Administrative Current
AccruedSellingGeneralAndAdministrativeCurrent
10831000
CY2023Q4 axsm Accrued Selling General And Administrative Current
AccruedSellingGeneralAndAdministrativeCurrent
9242000
CY2024Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
68766000
CY2023Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
46713000
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4536000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5927000
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
1575000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1659000
CY2024Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
493000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1280000
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
122176000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
90501000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
180000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
180000000
CY2024Q3 axsm Debt Instrument Accreted Final Payment Fee
DebtInstrumentAccretedFinalPaymentFee
3694000
CY2023Q4 axsm Debt Instrument Accreted Final Payment Fee
DebtInstrumentAccretedFinalPaymentFee
2610000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3692000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
4540000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
180002000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
178070000
CY2024Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4892000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4890000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
14630000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
12592000
CY2024Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
375000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
333000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1085000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
855000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
180000000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
180000000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
axsm Sublease Agreement Term
SubleaseAgreementTerm
P10Y
CY2024Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2024Q3 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P12M
axsm Finance Lease Liability Recognized In Exchange Of Right Of Use Asset
FinanceLeaseLiabilityRecognizedInExchangeOfRightOfUseAsset
4900000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
4200000
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.096
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
583000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
583000
us-gaap Operating Lease Cost
OperatingLeaseCost
1749000
us-gaap Operating Lease Cost
OperatingLeaseCost
1590000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
324000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
697000
CY2024Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
101000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
222000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
245000
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
415000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1976000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1594000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2521000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
1500000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2521000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
1037000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3204000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
339000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10467000
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
4885000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2400000
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
655000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8067000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
4230000
axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8462294
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
41.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1121896
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
83.43
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
664480
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
39.57
axsm Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Or Canceled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresOrCanceledInPeriod
465884
axsm Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Or Canceled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresOrCanceledInPeriodWeightedAverageExercisePrice
59.62
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8453826
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.2
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
369494
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8453826
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
46.2
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
369494
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5002481
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.4
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
282513
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
64.54
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
160900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21660000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16368000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
63232000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43705000
CY2024Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
300000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
1000000
CY2023Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
900000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
2400000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
79220
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
56.8
axsm Warrants Issued In Period
WarrantsIssuedInPeriod
0
axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
0
axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
0
axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
0
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
79220
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
56.8
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-64602000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-62199000
us-gaap Net Income Loss
NetIncomeLoss
-212304000
us-gaap Net Income Loss
NetIncomeLoss
-140587000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48140519
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48140519
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47117196
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47117196
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47703508
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47703508
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44783380
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44783380
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.14
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9502084
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9027695
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104762000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57794000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
266927000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
199070000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104762000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
57794000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
266927000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
199070000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64602000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62877000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-212304000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-139302000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-678000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1285000
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.009
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1300000
CY2024Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0

Files In Submission

Name View Source Status
0000950170-24-124758-index-headers.html Edgar Link pending
0000950170-24-124758-index.html Edgar Link pending
0000950170-24-124758.txt Edgar Link pending
0000950170-24-124758-xbrl.zip Edgar Link pending
axsm-20240930.htm Edgar Link pending
axsm-20240930.xsd Edgar Link pending
axsm-ex10_1.htm Edgar Link pending
axsm-ex10_2.htm Edgar Link pending
axsm-ex10_3.htm Edgar Link pending
axsm-ex10_4.htm Edgar Link pending
axsm-ex31_1.htm Edgar Link pending
axsm-ex31_2.htm Edgar Link pending
axsm-ex32_1.htm Edgar Link pending
axsm-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
axsm-20240930_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable